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ABSTRACT
A systematic and comparative study has been made starting from a naturally-occurring chalcone nucleus to design effective
antibacterial agents. The present investigation established 1,5-bis(2-hydroxyphenyl)pent-1,4-diene-3-one (1c) as a lead
compound with potential against a panel of pathogenic bacterial strains, Staphylococcus (coagulase negative), Escherichia coli,
Pseudomonas aeruginosa, Acenetobacter sp. and Klebsiella pneumoniae. Gentamycine and tetracycline were used as reference
drugs. The mode of antibacterial action of1cwas also studied by scanning electron microscopy, which showed membrane disrup-
tion and cell lysis of the organisms during the exposure of the tested compound. In vitro toxicity tests demonstrated that all the
bioactive compounds showed far less toxicity against human erythrocytes.
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1. Introduction
The development of untreatable resistant strains of pathogenic
bacteria, because of extensive use of several types of antibiotics
in clinical practice, is emerging as a serious problem before the
medicinal chemists throughout the world.1–3 Moreover, the use
of a wide variety of synthetic and semi-synthetic antimicrobial
chemotherapeutics is of prime concern for environmentalists,
due to their hazardous synthetic pathways. To yield better phar-
macologically acceptable antibacterial drugs with safer synthetic
methodology, the current approach is based on findings such as:
several naturally-occurring and synthetic compounds consisting
of chalcone as the core nucleus possess broad-spectrum biological
activity such as cytotoxicity,4 antitrichomal,5 antioxidant,6–8
tyrosinase inhibitory,9 anti-inflammatory,9 cancer chemopre-
ventive,10 antimitotic,11 analgesic,12 antitumour,13 antibacterial14–17
and antifungal activity.18 Many reports suggested that the number
and position of the hydroxyl group in the chalcone nucleus
showed tremendous influence on its biological activity.19 It is also
well documented that the carbonyl group in conjugation with
the double bond shows a profound effect20,21 on the activity of
various pharmacologically important compounds.
Thus, a series of known and unknown analogues of chalcone,
structurally modified with respect to the above mentioned
parameters (Scheme 1a–1d and Scheme 2a–2g), has been evalu-
ated against clinically isolated bacterial strains of Gram-positive
[Staphylococcus aureus and Staphylococcus (cougulase negative)]
and Gram-negative [Escherichia coli, Pseudomonas aeruginosa,
Acenetobacter sp. and Klebsiella pneumoniae] by disc diffusion and
microdilution methods. In addition, the mode of action of the
most effective compound of the series, 1c, was studied by
scanning electron microscopy (SEM).
2. Results and Discussion
The parent compound, chalcone (2a), showed moderate activ-
ity against two bacterial strains, K. pneumoniae (1) and S. aureus
(MIC = 500 µg mL–1) (Tables 1 and 2). Compound 1a was slightly
more active against these bacteria. Preliminary investigation for
antibacterial activity of compound 2c by the disc diffusion
method showed significant reduction in bacterial growth in
terms of inhibition around the disc against six test bacteria,
K. pneumoniae, Acenetobacter, S. aureus, Staphylococcus (coagulase
negative) and one strain of E. coli (1). The MIC was found in the
range of 500 µg mL–1. The biological activity data clearly revealed
that compound 1c had promising activity against all the test mi-
crobes with an MIC of 500 µg mL–1 against reference drug-
resistant strains of E. coli (2), Acenetobacter sp., Staphylococcus
(coagulase negative) and P. aeruginosa (also resistant to all the
tested compounds); 250 µg mL–1 against K. pneumonia (1)
(slightly sensitive to tetracycline with MIC 125 µg mL–1 for 50 %
inhibition), S. aureus (sensitive to both the reference drugs with
MIC 125 µg mL–1) and another strain of E. coli (1) and 125 µg mL–1
against K. pneumonia (2) (resistant to both the reference drugs).
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Scheme 1
A series of scanning electron microscope pictures was taken of
untreated cultures and also of cultures treated with compound
1c during 30 min of incubation. Untreated organisms appeared
as smooth and short rods (Figs. 1A and 1B). Bacterial cells treated
with the compound were found ruptured and lysed, as is clear
from Figs. 1C and 1D.
The in vitro cell cytotoxicity of 1c, 2a and 2c was investigated
using the haemolytic assay. The compounds were found to be
less toxic up to the tested concentration, that is, 1000 µg mL–1 and
lysed only 10.2 % 1c, 6.9 % 2a and 14 % 2c of human erythrocytes,
respectively, whereas at the same concentration, standard drugs
tetracycline and gentamycine lysed 33.1 % and 28.5 % of eryth-
rocytes, respectively (Fig. 2).
Chalcones are ubiquitous in plant cells as secondary metabo-
lites. In order to identify the part of the molecule responsible for
bioactivity, the basic nucleus of chalcone 2a (Fig. 3), consisting of
two benzene rings, A and B, was initially evaluated for antibacte-
rial activity. Its activity was comparable with that of standard
drugs (Tables 1 and 2).
To address the effect of structural differences on their respec-
tive antimicrobial activities we examined it in relation to the
number and position of the double bond and/or the hydroxyl
group. First we introduced an additional double bond in conju-
gation with benzene rings A (1a) and B (2b). Biological data
clearly indicate that the introduction of a double bond in conju-
gation with ring B (2b) completely diminished the activity,
however its symmetrical distribution around the carbonyl group
(1a) showed a slightly positive influence on the activity of the
chalcone nucleus against K. pneumonia (1) and S. aureus. It
prompted us further to extend the double bond symmetrically
around the carbonyl group (1b). Contrary to our expectation the
compound was found to be inactive. We can say that the impor-
tance of this study lies in the optimization of the extension of the
conjugation in the molecule. The structure of compound 1a
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Scheme 2
Table 1 Disc diffusion method: zone of inhibition (mm) for all strains.
Bacteria 1a 1b 1c 1d 2a 2b 2c 2d 2e 2f 2g Gentamycine Tetracycline
E. coli (1) a – – 8 – – – 7 – – – – – –
E. coli (2) a – – 7 – – – – – – – – – –
K. pneumoniae (1) a 8 – 11 – 7 – 7 – – – – – 8
K. pneumoniae (2) a – – 20 – – – 10 – – – – – –
Acenetobacter – – 10 – – – 7 – – – – – –
S. aureus 11 – 18 – 11 – 13 – – – – 21 20
Staphylolcocus – – 8 – – – 6.5 – – – – – –
(coagulase negative)
P. aeruginosa – – 9 – – – – – – – – – –
a Two different strains of same bacteria isolated from two different sources.
Table 2 Microdilution method: MIC values (µg  mL–1) for all strains.
Bacteria 1a 1b 1c 1d 2a 2b 2c 2d 2e 2f 2g Gentamycine Tetracycline
E. coli (1) a – – 250 – – – 500 – – – – – –
E. coli (2) a – – 500 – – – – – – – – – –
K. pneumonieae (1) a 500 – 250 – 500 b – 500 b – – – – – 125 b
K. pneumonieae (2) a – – 125 – – – 500 – – – – – –
Acenetobacter – – 500 – – – 500 b – – – – – –
S. aureus 500 – 250 – 500 – 500 – – – – 125 125
Staphylolcocus – – 500 – – – 500 b – – – – – –
(coagulase negative)
P. aeruginosa – – 500 – – – – – – – – – –
a Two different strains of same bacteria isolated from two different sources.
b MIC for only 50 % inhibition.
must be kept intact to preserve its efficacy during further struc-
tural modifications.
To ascertain the effect of the position and number of the
hydroxyl group on the activity of the parent compound, 2c, 2d
and 2e, with hydroxylation at the 2, 2’ and 4’ positions, respec-
tively, were screened against the bacteria. Compound 2c was
found to be more potent compared with the reference drugs,
exhibiting varying broad-spectrum antibacterial activity against
K. pneumonia (1 and 2), Acenetobacter, S. aureus, Staphylococcus
(coagulase negative) and one strain of E. coli (1). This strongly
suggests that hydroxylation at the 2 position somehow plays an
important role in the induction of bioactivity in the parent com-
pound. A comparative investigation of the bioactivity of com-
pounds 2c, 2f and 2g established that the presence of a hydroxyl
group at the 2’ or 4’ positions completely inhibited the bio-
activity of compound 2c.
Based on the above positive findings, compound 1c, bearing
optimum extended conjugation around the carbonyl group and
2-hydroxyl groups, was studied for its antibacterial activity.
Surprisingly the compound showed tremendous activity
against all the test bacteria. Encouraged by the results, its mode
of action was further studied by SEM. Scanning electron micros-
copy of changes in the bacteria induced by 1c revealed morpho-
logical alterations which correlated well with their mechanism
of action. Knowledge of the morphological responses of bacterial
species to a variety of tested compounds may allow some predic-
tion of therapeutic potential and may also indicate organism and
compound interaction.
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Figure 1 Scanning electron microscopy of cells from broth cultures; (A) untreated control culture of E. coli (1), × 5000; (B) untreated control culture of
E. coli (1), ×10 000; (C) E. coli (1) treated with 1c, 125 µg mL–1 30 min, ×5000; (D) E. coli (1) treated with 1c, 125 µg mL–1, ×10 000, 30 min.
Figure 2 Haemolytic activities of tested bioactive compounds.
Furthermore a methoxy group on both the rings (1d) in the
active compound 1c retarded the activity, as mentioned previ-
ously by other authors22 in their studies.
The significance of the present investigation lies in the fact that
the syntheses of the basic nucleus of chalcone and all reported
modifications were conducted at ambient temperature and
pressure with no use of hazardous chemicals as catalysts or
solvents. To the best of our knowledge such systematic and
comparative studies, starting from a bioactive nucleus of natural
origin to obtain potent antibacterial agents through safer
synthetic routes, has never been made before. The information
gained in the present approach will help us to discover new
potential anti-Gram-positive and anti-Gram-negative bacterial
agents with 1c as the lead compound.
3. Experimental
All melting points were determined in open capillary tubes
and are uncorrected (Table 3). IR spectra were recorded on a
Perkin Elmer BX-II spectrophotometer (Singapore) using
KBr pellets. The spectra showed characteristic bands at
3100–2900 cm–1 and 1610–1570 cm–1, due to aromatic ring
skeleton vibrations. The shift in wavenumber from the normal
range of the C=O band of 1700 cm–1 to the range of
1698–1650 cm–1 confirmed the presence of a conjugated carbonyl
group. A band in the 3100–2900 cm–1 range confirmed the
-CH=CH- skeleton. For 1c, 2c, 2d, 2e, 2f and 2g, bands near
778 cm–1 and 696 cm–1 signified the presence of monosubstituted
benzene. A band near 830 cm–1 due to a disubstituted benzene
was observed for 1d. The presence of an OH group in 1c, 1d, 2c,
2d, 2e, 2f and 2g was confirmed by a band in the range of
3455–3350 cm–1. The UV spectra were recorded on a UNICAM
UV-4 spectrophotometer (Cambridge, UK) using ethanol as
solvent. The UV spectra showed a n → π* transition (λmax in the
range of 300–340 nm) and a π → π* transition (λmax in the range of
220–280 nm) with an increment of wavelength indicating the
presence of a conjugated carbonyl group. 1H NMR (CDCl3)
analysis was done with a Bruker model ACP 300 spectrometer
(Zurich, Switzerland) and CHN analysis was done with Element
Analysensysteme GmbH VarioEL (Hanau, Germany). The
1H NMR spectra of lead compound 1c showed a peak at δ 7.2–7.6
(m, 8H, Ar), δ 7.4–7.8 (s, 4H, HC=CH) and δ 6.9–7.0 ppm (s, 2H,
OH). The 1H NMR spectra of other compounds showed medium
intensity peaks for aromatic protons in the range of δ 7.2–
7.9 ppm, strong peaks for -HC=CH- protons and -OH protons in
the ranges of δ 7.5–8 and δ 6.5–7.3 ppm, respectively. The spec-
tral data confirmed the assigned structures. The CHN results
were found to be in accordance with their expected values.
All the reported structural modifications were carried out by
the classical aldol condensation involving base-catalyzed
condensation of the desired carbonyl compounds followed by
dehydration forming α,β-unsaturated carbonyl compounds.
The detailed synthetic route is described below.
3.1. 1,5-Diarylpent-1,4-diene-3-one/1,9-diarylnon-1,3,6,8-
tetraene-5-one (1a–1d)
In a two-necked round-bottom flask equipped with a mechanical
stirrer, a solution of the desired aldehyde (0.01 mol) was taken in
the required amount of alcoholic NaOH. Acetone (0.02 mol) was
added slowly from a dropping funnel with vigorous shaking.
The temperature of the reaction mixture was maintained at
25 °C. Reaction was completed in 40–45 min with the formation
of a yellow precipitate. The precipitate was filtered out and
recrystallized from the appropriate solvent23 (Scheme 1).
3.2. 1,3-Diarylprop-2-ene-1-one/1,5-diarylpent-2,4-
diene-1-one (2a–2g)
Acetophenone or substituted acetophenone (0.01 mol) was
taken in alcoholic NaOH in a bolt head flask, provided with a
mechanical stirrer. The desired aldehyde (0.01 mol) was then
added from a dropping funnel with stirring at 25 °C. The reac-
tion mixture was further stirred vigorously for 2–3 h and was
kept in a refrigerator overnight. The compound was filtered,
washed and recrystallized from the appropriate solvent23
(Scheme 2).
3.3. Antibacterial Activity
3.3.1. Preliminary Screening: Disc Diffusion Method
This is one of the most widely used methodologies for the
rapid screening of antibacterial agents.28 A loopful of culture was
taken from the slants of individual bacterial strain and inocu-
lated in 25 mL of sterile nutrient broth. Cultures were incubated
at 37 °C and 120 rpm for 4–6 h until the culture exhibited expo-
nential growth. 100 µL of actively growing culture (an OD650 of
1.0) was evenly spread with the help of a spreader onto the
surface of a nutrient agar plate. A concentration of 20 mg mL–1 of
each compound (1a–1d and 2a–2g) and a blank (solvent in which
each compound was dissolved) was taken. The discs (5 mm
diameter), made by using a standard punching machine from
Whatman filter paper (#3) were sterilized by autoclaving them
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Table 3 Physical characterization of the compounds.
Compound Molecular formula IUPAC name Melting point/°C Yield/% Reference
1a C17H14O 1,5-diphenyl pent-1,4-diene-3-one 110 88 24
1b C21H18O 1,9-diphenylnon-1,3,6,8-tetraene-5-one 96 78 24
1c C17H14O3 1,5-bis(-2-hydroxyphenyl)pent-1,4-diene-3-one 112 77 18
1d C19H18O5 1,5-bis(2-hydroxy-4-methoxyphenyl)penta-1,4-dien-3-one 116 76
2a C15H12O 1,3-di(phenyl)prop-2-ene-1-one 53 80 18
2b C17H14O 1,5-di(phenyl)pent-2,4-diene -1-one 70 86
2c C15H12O2 1-phenyl, 3-(2-hydroxyphenyl) prop-2-ene-1-one 115 83 18
2d C15H12O2 1-(4-hydroxyphenyl) 3-phenyl prop-2-ene-1-one 80 78 25
2e C15H12O2 1-(2-hydroxyphenyl) 3-phenylprop-2-ene-1-one 89 85 26
2f C15H12O3 1-(4-hydroxyphenyl), 3-(2-hydroxyphenyl) prop-2-ene-1-one 200 74 27
2g C15H12O3 1-(2-hydroxyphenyl), 3-(2-hydroxyphenyl) prop-2-ene-1-one 166 79 26
Figure 3 The basic structure of chalcone.
in a glass bottle. A solution of the compounds was added to each
disc (6 µL disc–1) placed on a sterile petriplate and dried for
3–5 min. The impregnated discs were placed on a pre-inoculated
agar surface with sterile forceps and gently pressed down to
ensure contact.
The experiment was done in triplicate. The plates were incu-
bated at 37 °C for 16–18 h. The degree of inhibition of the test
compounds was observed by the formation of zones around the
spotted compounds and compared with the zone of the blank.
3.3.2. Determination of Minimum Inhibitory Concentration:
Microdilution Method
Antimicrobial susceptibility testing was carried out using the
National Committee for Clinical Laboratory Standards (NCCLS)
microdilution broth assay. Briefly, the bacterial strains were
grown in nutrient broth (HIMEDIA) until exponential growth
was achieved. Test compounds were dissolved in DMSO/water
to make a series of two-fold dilutions.
90 µL of 2–7 × 10–5 CFU mL–1 of bacterial sample per mL of
nutrient broth (HIMEDIA) was dispensed into a 96-well poly-
propylene microtitre plate (SIGMA). Then 10 µL of serially
diluted compound was added. The microtitre plates were incu-
bated overnight at 37 °C and the absorbance was read at 630 nm.
Uninoculated nutrient broth was used as a negative control. The
tests were carried out in triplicate. The minimum inhibitory
concentration (MIC) was taken as the lowest concentration of
compound that inhibited more than 90 % growth of the microor-
ganism.
3.4. Scanning Electron Microscopy
For the SEM study, nutrient broth (HIMEDIA) was inoculated
with E. coli (1) and incubated at 37 °C for 24 h. A sample was then
subcultured into fresh broth to obtain cultures in the logarithmic
phase of growth. A specified concentration of 125 µg mL–1 of 1c
was added to the culture in the logarithmic phase of growth (4
h).The test organism was exposed to 1c for 30 min at 37 °C. In this
study, the control culture was manipulated in an identical
manner except that it was not exposed to the compound. To
prepare the specimens of E. coli (1) for SEM, a sample (1.0 mL) of
the broth culture was washed three times with phosphate buffer
(pH 6.8) by centrifuging. All specimens were treated simulta-
neously so that observed differences between specimens were
not due to differences in preparation. These specimens were
examined with a LEO 435VP, Version V3.0, Oxford Instruments
INCA X-Sight scanning electron microscope (Oxford, UK).
3.5. Haemolytic Assay
The haemolytic activities of the compounds were determined
using human red blood cells (hRBC).29 The hRBC were centri-
fuged for 15 min to remove the buffy coat and washed three
times with phosphate-buffered saline (PBS: 35 mmol L–1 phos-
phate buffer, pH 7.0/150 mmol L–1 NaCl). The suspended hRBC
(100 µL, 4 % (v/v)) in PBS was plated into sterilized 96-well plates
and then 100 µL of the compound solution was added to each
well. The plates were incubated for 1 h at 37 °C and centrifuged
at 1500 rpm for 5 min. Aliquots (100 µL) of the supernatant were
transferred to 96-well plates, where haemoglobin release was
monitored using ELISA plate reader (Benchmark Plus
Microplate Spectrophotometer, Bio-Rad Laboratories, Hemel
Hempstead, UK) by measuring the absorbance at 414 nm.
Percentage haemolysis was calculated by the following formula:
% Haemolysis = [(Abs414 nm in the compound solution – Abs414 nm in
PBS)/(Abs414 nm in 0.1 % Triton X-100 – Abs414 nm in PBS)] × 100
Zero percentage and 100 % haemolysis were determined in
PBS and 0.1% Triton X-100, respectively.
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